Grifols, S.A. (BME: GRF)
Health Care · Biotechnology · ES
€9.91
-0.02% today · -19.9% 1Y
Grifols, S.A. (BME: GRF) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.97B and employs 25,258 people.
Over the last twelve months the share price has lost 19.9%, trading between 8.43 and 12.87.
Tweenvest scores Grifols, S.A. across four factors: quality 62/100, value 73/100, growth 37/100, dividend 66/100. Its strongest factor is value.
GRF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.97B
- Revenue (TTM)
- $8.48B
- P/E
- 15.02
- EPS
- 0.66
- Dividend yield
- 3.00%
- Beta (5Y)
- 1.19
- 52-week high
- €12.87
- 52-week low
- €8.43
- Avg volume (3M)
- —
- Shares outstanding
- 680.58M
- Employees
- 25,258
- Next earnings
- —
About Grifols, S.A.
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
- ISIN
- ES0171996087
- Founded
- 1909
- Listed since
- May 17, 2006
- Exchange
- Bolsas y Mercados Espanoles
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.